US Drug Security Focus Amid War and Pandemics

healthcare security – With hantavirus spreading and global tensions rising, the U.S. and Europe are rethinking drug supply chains and healthcare resilience.

A new scramble for healthcare security is taking shape as governments confront the uncomfortable lesson of COVID-19: modern medical systems are deeply dependent on supplies and ingredients sourced from abroad.

That vulnerability is now being stress-tested by multiple pressures at once. from the spread of hantavirus to persistent regional instability that can disrupt shipping routes.. For Western governments. the message is clear—health cannot be treated as a purely domestic problem when critical medicines and their raw materials flow through international supply chains that can fail quickly.

The memory of COVID-19’s early chaos still lingers.. During the pandemic’s first weeks. countries used export controls and purchasing access to manage where personal protective equipment could be bought.. Nations viewed as cooperative were sometimes allowed to purchase essentials such as face masks and gloves, while others were blocked.. The pattern was not limited to one supplier or one region: Beijing’s approach toward Europe. and the unequal distribution of medical materials even among partners. underscored how geopolitics can quickly turn into healthcare leverage.

Even where export bans were not driven by overt hostility. the result was the same for many governments: restrictions were often justified as necessary to keep domestic supplies available.. That practical logic helped ensure stockpiles at home. but it also exposed a deeper structural risk—an assumption that trade networks would remain stable even during global emergencies.

COVID-19 has largely eased in many places, but the policy aftermath may return in new forms.. Today, Western countries rely on more than protective equipment.. In testimony to the U.S.. Congress this March, healthcare economist Marta E.. Wosinska from the Brookings Institution highlighted how supply dependence reaches into the manufacturing chain itself.. She pointed to the role of Chinese-produced active ingredients in U.S.. generic drug volumes and noted that a significant share of the key starting materials used in U.S.-approved active ingredients is sole-sourced from China.

Europe faces similar fragility.. The continent’s industrial capacity for key medicine production has narrowed over time, leaving fewer domestic options for critical manufacturing.. For the United Kingdom. a House of Lords report in February concluded that most medicines are manufactured in the UK or depend on essential ingredients coming from outside the country. particularly from India and China or from other single-source suppliers.

The underlying economic arrangement is straightforward: China is positioned as a major exporter of active ingredients. while India exports a large share of finished products.. For generics—the most common category of drugs used in prescriptions—companies producing in China and India dominate global supply.. In calm periods, that specialization lowers costs.. In crisis periods, it can also turn dependency into strategic risk.

Worsinska’s testimony. and related observations from industry research. feed into a broader argument now made across policy circles: healthcare should be treated as part of national security.. The concern is not only pandemics, but also what might happen if major wars disrupt transport and manufacturing capacity.. In that scenario, armed forces and civilian health systems could end up competing for the same medicines and medical supplies.

That dynamic is already showing up in how governments think about infectious threats.. Leaders are taking the hantavirus situation—reported in connection with a cruise liner currently docked off the Canary Islands—seriously. reflecting the reality that outbreaks can force rapid mobilization of medical resources.

The European response is moving from discussion toward legislation.. The EU is working to reshore manufacturing of active ingredients, critical medicines, and essential drugs such as antibiotics and insulin.. The EU Critical Medicines Act passed overwhelmingly in the European Parliament in January. and on May 12 the EU Council and European Parliament agreed on a revised version.. Both institutions are expected to sign off within weeks.

The shift is intended to reduce the risk that geopolitical shocks can immediately translate into medicine shortages.. Yet officials and experts also acknowledge that reshoring cannot mean every drug will be produced locally.. Diederik Stadig. a healthcare economist at ING Research. said the approach effectively accepts that many generics will continue being produced in Asia. while focusing reshored production on a larger share of medicines viewed as critical.. That is a policy trade-off: local manufacturing is expected to carry higher costs.. Stadig pointed to an estimated price increase in the range of about 20% to 40% for the medicines produced at home.

Still. the argument is that in a tense and sometimes hostile world. domestic capability for critical medicines matters even if it is more expensive.. Post-Brexit. the UK will not participate in the EU effort in the same way. and the House of Lords advised Britain to work with international partners to build a broader set of medicine resilience measures so the UK is not left behind as other countries expand their health supply protections.

In the United States, the strategy is more contested.. Stadig characterized U.S.. efforts as more protectionist when it comes to manufacturing incentives, highlighting that the approach has involved tariffs.. He noted that tariffs have mostly targeted branded pharmaceuticals made in Europe. while generics would largely remain produced in Asia because of scale advantages.

The timeline he cited includes a 15% tariff the United States imposed last July on the EU. covering pharmaceuticals among other products.. Then in September, President Donald Trump announced a planned 100% tariff on imports of branded or patented pharmaceutical products beginning Oct.. 1, with exemptions for companies building manufacturing plants in the United States.. He also noted that generics manufacturers were not included under those tariffs.. Trump did not carry the plan forward at the time, but the threat was renewed last month.

The concern raised by experts is that using tariffs to pressure European makers while not similarly targeting Chinese suppliers may be a risky way to build health security.. If the goal is resilience. policymakers need strategies that reflect where the true dependencies sit across the full supply chain rather than only addressing where finished branded products happen to be produced.

At the same time, the U.S.. is pursuing an approach that experts view as potentially more aligned with long-term security: investment in innovation.. Stadig said Washington is using government funds to keep pace with China in biomedical innovation, biotechnology, and medical artificial intelligence.. He pointed to an estimate that the share of the global pipeline of new innovative molecules associated with China has risen sharply over the past decade—from 4% in 2014 to about one-third today. according to ING’s assessment.

For now, the challenge confronting both sides of the Atlantic is that resilience does not change overnight.. Supply chains and industrial specialization built over decades of globalization cannot be reversed quickly. even when governments agree on the direction.. What is changing is political urgency: war and pandemic risks are pushing health systems higher up national security agendas.

There is also a note of cautious optimism in how policymakers are framing solutions.. The path toward greater medicine independence may depend not only on reshoring production. but also on building stable relationships with partners.. For countries that maintain close and respectful ties. the promise is that health security can be strengthened without assuming a worst-case breakdown of global trade every time tensions rise.

healthcare security drug supply chains U.S. tariffs EU Critical Medicines Act medical resilience hantavirus